Results 151 to 160 of about 50,167 (231)
IFN‐γ‐Associated Signaling Networks in Interstitial Lung Disease Associated With Sjögren's Disease
ABSTRACT Background Sjögren's disease (SD) is a chronic systemic autoimmune disorder that can affect multiple organ systems. Interstitial lung disease (ILD) is a clinically significant pulmonary manifestation of SD and is associated with impaired quality of life and increased mortality.
Qianqian Chen +5 more
wiley +1 more source
This review delineates the multifaceted roles of natural killer (NK) cells in the central nervous system, spanning direct cytolysis, immunoregulation, and crosstalk with the brain microenvironment. We evaluate the translational potential and challenges of NK cell immunotherapies for a spectrum of neurological conditions.
Kaihang Deng, Wai Po Chong
wiley +1 more source
Herpesviridae Reactivation and Therapeutic Outcomes in Patients with Ulcerative Colitis Treated with Tofacitinib. [PDF]
Harnik S +13 more
europepmc +1 more source
Arthritis Care &Research, Volume 78, Issue 10, Page 1317-1323, October 2026.
Pamela F. Weiss, Hermine I. Brunner
wiley +1 more source
A panel of 18 dermatologists participated in a three‐round Delphi‐based consensus process to generate a standardized framework for the diagnosis and management of alopecia areata (AA) in Asia Pacific. Recommendations focus on practicality and clinical relevance within the regional context.
Rodney Sinclair +17 more
wiley +1 more source
Real-world effectiveness of tofacitinib in monotherapy or in combination with csDMARDs in patients with rheumatoid arthritis: A collaboration between Dutch registries (TOFADUDAP study). [PDF]
Nevins IS +8 more
europepmc +1 more source
Genetic Risk Meets the Intestinal Barrier
Top: At increasing cellular resolution, the Alegbe et al. report that expression quantitative trait loci (eQTLs) are enriched in enhancer regions rather than promoters. They speculate that enhancer eQTLs only come into effect during certain cellular contexts, making them more tolerable. Bottom: Alegbe et al.
J. L. E. Tearle, K. R. James
wiley +1 more source
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor that is under investigation for the treatment of psoriatic arthritis. We evaluated tofacitinib in patients with active psoriatic arthritis who previously had an inadequate response to conventional
Graham, Daniela +11 more
core
Tofacitinib-Associated Acne in a Young Patient With Severe Atopic Dermatitis. [PDF]
Oujdi S, El Jouari O, Gallouj S.
europepmc +1 more source
ACR Open Rheumatology, Volume 8, Issue 10, October 2026.
Yuqing Dan, Liling Zhao, Qiong Fu
wiley +1 more source

